Following a recommendation from its Furosemide Advisory Committee (FAC), the Horseracing Integrity and Safety Authority's Board of Directors approved $773,500 in grant funding for three scientific studies on the use of furosemide (also known as “Lasix”) to be conducted over the next two years by the Nationwide Children's Hospital, the University of Florida College of Veterinary Medicine and Washington State University, HISA said in a Wednesday release.
The studies will examine the 48-hour period before the start of a Covered Horserace, including the effects of furosemide on equine health and the integrity of competition. Researchers will be required to present final reports on their findings to the FAC on or before Jan. 31, 2026.
“The Furosemide Advisory Committee is grateful to the expert researchers who responded to our request for proposals and look forward to partnering with Nationwide Children's Hospital, the University of Florida College of Veterinary Medicine and Washington State University on this important research,” said FAC Chairman Dr. Scott Palmer, VMD. “The lifelong health and well-being of Thoroughbreds is our top priority. This work will help ensure we have policies in place to safeguard these remarkable animals and the integrity of the sport.”
Under the Horseracing Integrity and Safety Act, HISA is required to fund scientific research on the topic of furosemide to inform the FAC's future recommendations to the HISA Board on whether and how to amend their existing furosemide regulations.
A request for proposals was issued by HISA in August 2023. Out of those submitted, the following were recommended by the FAC and approved:
Examining Associations Between Furosemide Treatment & Racehorse Health and Welfare
Principal Investigator: Amanda Waller, Bsc, PhD, Research Scientist, Center for Clinical and Translational Research, Nationwide Children's Hospital
This study will examine the effects of race day furosemide treatment on the health and welfare of Thoroughbreds as well as their long-term racing performance. An analysis will be conducted to assess the association between pre-race furosemide administration and fatal injury, while also comparing the performance metrics–including lifetime earnings, career length, lifetime starts, starts per year, placings and average speed figures–of horses that raced exclusively on furosemide as 2-year-olds and horses that did not receive furosemide as juveniles.
Effects of Repeated Furosemide Administration on Electrolyte Homeostasis and Bone Density in Healthy Adult Exercising Thoroughbreds
Principal Investigator: SallyAnne L. DeNotta, DVM, PhD, DACVIM., Clinical Assistant Professor, Large Animal Medicine, University of Florida College of Veterinary Medicine
This study will examine the effects of repeated furosemide administration on electrolyte homeostasis, parathyroid response and urinary electrolyte excretion in exercising adult Thoroughbreds. The study will also examine the effects of repeated administration on bone density and strength using minimally invasive methods of measurement, including DEXA scan and OsteoProbe.
Does Pre-Race Administration of Furosemide to Thoroughbred Racehorses Prolong Their Racing Careers?
Principal Investigator: Warwick Bayly, BVSc, PhD, DACVIM, Professor, Department of Veterinary Clinical Sciences, Washington State University
This study will examine the impact of severe exercise-induced pulmonary hemorrhage (EIPH) on horses' careers and the health of the racing industry more broadly. In doing so, the study will assess whether regular furosemide treatment is associated with more career starts and greater longevity and the impact of banning furosemide for 2-year-olds on the duration of their careers and number of lifetime starts. The study will also seek to determine the extent to which severe EIPH impacts the number of subsequent starts, the periods between them and, when applicable, the time between the diagnosis of severe EIPH and retirement.